Findit, Inc. Provides Earnings Results for the Third Quarter Ended 30 September 2019
October 22, 2019 at 03:20 pm
Share
Findit, Inc. Provides Earnings Results for the Third Quarter Ended 30 September 2019. Company revenue increase in the third quarter over the same period one year ago of 178 %. With revenues of $162,591.00 versus $58,468.00. Earnings for the third quarter ending September 30, 2019 of $24,995.00 an increase of the same period last year of 532%. While the third quarter has been a combination of revenue streams from their full-service social networking content management platform Findit.com it also added revenue from its first quarter of entering into the B2B CBD Topical space.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.